Godavari Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE362C01012
  • NSEID:
  • BSEID: 530317
INR
92.00
-0.78 (-0.84%)
BSENSE

Apr 02

BSE+NSE Vol: 26.97 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Denis Chem Lab
Godavari Drugs
Makers Labs.
Balaxi Pharma
Mercury Labs
Tyche Industries
Lactose (India)
Bal Pharma
Pharmaids Pharma
Alpa Laboratorie
Krebs Biochem
Why is Godavari Drugs Ltd ?
1
Weak Long Term Fundamental Strength with a -0.27% CAGR growth in Net Sales over the last 5 years
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.27 times
2
The company has declared Negative results for the last 4 consecutive quarters
  • PAT(9M) At Rs 2.93 cr has Grown at -45.83%
  • OPERATING CF(Y) Lowest at Rs 11.20 Cr
  • NET SALES(9M) At Rs 75.96 cr has Grown at -21.64%
3
Below par performance in long term as well as near term
  • Along with generating -36.66% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Godavari Drugs for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Godavari Drugs
-2.23%
-0.83
44.22%
Sensex
-4.3%
0.44
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-2.98%
EBIT Growth (5y)
1.36%
EBIT to Interest (avg)
2.32
Debt to EBITDA (avg)
3.62
Net Debt to Equity (avg)
1.37
Sales to Capital Employed (avg)
2.09
Tax Ratio
24.39%
Dividend Payout Ratio
0
Pledged Shares
0.22%
Institutional Holding
0.50%
ROCE (avg)
13.39%
ROE (avg)
13.97%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
27
Industry P/E
31
Price to Book Value
2.15
EV to EBIT
19.10
EV to EBITDA
14.57
EV to Capital Employed
1.49
EV to Sales
1.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.13%
ROE (Latest)
8.08%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company
Icon
NO KEY POSITIVE TRIGGERS
-4What is not working for the Company
NET SALES(Q)

Lowest at Rs 22.18 cr

EPS(Q)

Lowest at Rs 1.01

Loading Valuation Snapshot...
Here's what is not working for Godavari Drugs
Net Sales - Quarterly
At Rs 22.18 cr has Fallen at -15.9% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 26.38 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Net Sales - Quarterly
Lowest at Rs 22.18 cr
in the last five quarters
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Earnings per Share (EPS) - Quarterly
Lowest at Rs 1.01
in the last five quarters
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (Rs)